Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

Authors: Sibylle Loibl, Joyce O’Shaughnessy, Michael Untch, William M. Sikov, Hope S. Rugo, Mark D. McKee, Jens Huober, Mehra Golshan, Gϋnter von Minckwitz, David Maag, Danielle Sullivan, Norman Wolmark, Kristi McIntyre, José Ponce, Otto Metzger, Priya Rastogi, W. Fraser Symmans, Xuan Liu, Charles E. Geyer - The Lancet 2018 cited by 771